The United Laboratories International Unit's Infection Drug Passes Chinese Regulator's Consistency Evaluation

MT Newswires Live
02/09

The United Laboratories International (HKG:3933) said the Roxithromycin Capsules passed China's National Medical Products Administration's consistency evaluation of quality and efficacy for generic drugs, according to a Monday Hong Kong bourse filing.

The drug was submitted by unit Zhuhai United Laboratories' Zhongshan Branch.

Roxithromycin Capsules are indicated to treat infections of the ear, nose and throat, respiratory tract, skin and soft tissues, and the genitourinary tract caused by pathogens susceptible to roxithromycin.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10